Skip to content

바이오 부문

BIO INFO

바이오 사업 부문

KPS BIO INFO

bai-sec-01

VISION

Innovative BioConvergence Company for Healthier Life

MISSION

Lead New Therapeutic Paradigm via Converging Bio and Information Technology

bai-sec2-01

5-YEAR PLAN

  • Establish Growth Engine Focused on Cancer and Digital Therapy
  • Diversify Portfolio to Reinforce its Value

Business Areas 
of Interest.

Business Areas
of Interest.

2020 KEY EVENTS.

CANCER THERAPEUTICS_

  • In-Licensing 1st Oncology Product, Nerlynx®
  • NDA Filing for Nerlynx® in Korea
  • Initiate/Assess Next In-Licensing Oncology Products
  • IDE* Filing for 1st DTx Products in US
  • Initiate Clinical Trial for 1st DTx Product in US
  • Strategy Investment to Digital Healthcare Space

DIGITAL THERAPEUTICS_

*IDE: Investigational Device Exemption